0001209191-17-057661.txt : 20171020 0001209191-17-057661.hdr.sgml : 20171020 20171020171228 ACCESSION NUMBER: 0001209191-17-057661 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171012 FILED AS OF DATE: 20171020 DATE AS OF CHANGE: 20171020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crowley John F CENTRAL INDEX KEY: 0001400973 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 171147574 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2017-10-12 2017-10-17 0 0001178879 AMICUS THERAPEUTICS INC FOLD 0001400973 Crowley John F C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 1 1 0 0 Chairman & CEO Common Stock 2017-10-12 4 M 0 380000 14.2495 A 708001 D Common Stock 2017-10-12 4 S 0 380000 14.2495 D 328001 D Common Stock 2017-10-13 4 M 0 22160 14.7503 A 350161 D Common Stock 2017-10-13 4 S 0 22160 14.7503 D 328001 D Common Stock 2017-10-16 4 M 0 47135 14.75 A 375136 D Common Stock 2017-10-16 4 S 0 47135 14.75 D 328001 D Common Stock 64895 D Stock Options (right to buy) 6.45 2017-10-12 4 M 0 5783 0.00 D 2016-02-15 2022-02-15 Common Stock 5783 131024 D Stock Options (right to buy) 4.38 2017-10-12 4 M 0 13622 0.00 D 2016-06-04 2022-06-04 Common Stock 13622 136378 D Stock Options (right to buy) 3.53 2017-10-12 4 M 0 3462 0.00 D 2017-01-28 2023-01-28 Common Stock 3462 161538 D Stock Options (right to buy) 2.52 2017-10-12 4 M 0 165000 0.00 D 2017-06-18 2023-06-18 Common Stock 165000 0 D Stock Options (right to buy) 3.19 2017-10-12 4 M 0 192133 0.00 D 2015-01-03 2024-01-03 Common Stock 192133 20972 D Stock Options (right to buy) 3.53 2017-10-13 4 M 0 22160 0.00 D 2017-01-28 2023-01-28 Common Stock 22160 139378 D Stock Options (right to buy) 3.53 2017-10-16 4 M 0 47135 0.00 D 2017-01-28 2023-01-28 Common Stock 47135 92243 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares. /s/ John F. Crowley 2017-10-20